Galectin-9 Expression is Correlated to Cervical Squamous Cell Carcinoma Progression and Overall Survival

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Mayadev JS, Ke G, Mahantshetty U, et al. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer. Int J Gynecol Cancer. 2022;32(3):436–445. doi:10.1136/ijgc-2021-003001
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349
   PubMed Web of Science ®Google Scholar
• Yang R, Sun L, Li CF, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832. doi:10.1038/s41467-021-21099-2
   PubMed Web of Science ®Google Scholar
• Elola MT, Ferragut F, Méndez-Huergo SP, et al. Galectins: multitask signaling molecules linking fibroblast, endothelial and immune cell programs in the tumor microenvironment. Cell Immunol. 2018;333:34–45. doi:10.1016/j.cellimm.2018.03.008
   PubMed Web of Science ®Google Scholar
• Liu FT, Stowell SR. The role of galectins in immunity and infection. Nat Rev Immunol. 2023;23(8):479–494. doi:10.1038/s41577-022-00829-7
   PubMed Web of Science ®Google Scholar
• Zhou X, Sun L, Jing D, et al. Galectin-9 expression predicts favorable clinical outcome in solid tumors: a systematic review and meta-analysis. Front Physiol. 2018;9:452. doi:10.3389/fphys.2018.00452
   PubMed Web of Science ®Google Scholar
• Choi S, Kook MC, Kook MC, et al. Prognostic value of tumoral expression of galectin-9 in gastric cancer. Turkish J Gastroenterol. 2017;28(3):166–170. doi:10.5152/tjg.2017.16346
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Dong JH, Chen YW, et al. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J Cancer Prev. 2012;13(6):2503–2509. doi:10.7314/APJCP.2012.13.6.2503
   PubMedGoogle Scholar
• Punt S, Thijssen VL, Vrolijk J, et al. Galectin-1, −3 and −9 expression and clinical significance in squamous cervical cancer. PLoS One. 2015;10(6):e0129119. doi:10.1371/journal.pone.0129119
   PubMed Web of Science ®Google Scholar
• John S, Mishra R. Galectin-9: from cell biology to complex disease dynamics. J Biosci. 2016;41(3):507–534. doi:10.1007/s12038-016-9616-y
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Heusschen R, Caers J, et al. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta. 2015;1855(2):235–247. doi:10.1016/j.bbcan.2015.03.003
   PubMed Web of Science ®Google Scholar
• Nobumoto A, Nagahara K, Oomizu S, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 2008;18(9):735–744. doi:10.1093/glycob/cwn062
   PubMed Web of Science ®Google Scholar
• Heusschen R, Griffioen AW, Thijssen VL. Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta. 2013;1836(1):177–185. doi:10.1016/j.bbcan.2013.04.006
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245–1252. doi:10.1038/ni1271
   PubMed Web of Science ®Google Scholar
• Sánchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4(11):1093–1101. doi:10.1038/ni987
   PubMed Web of Science ®Google Scholar
• Pang N, Alimu X, Chen R, et al. Activated galectin-9/TIM3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J. 2021;35(7):e21556. doi:10.1096/fj.202100013R
   PubMed Web of Science ®Google Scholar
• Yasinska IM, Sakhnevych SS, Pavlova L, et al. The Tim-3-Galectin-9 pathway and Its regulatory mechanisms in human breast cancer. Front Immunol. 2019;10:1594. doi:10.3389/fimmu.2019.01594
   PubMed Web of Science ®Google Scholar
• Yamauchi A, Kontani K, Kihara M, et al. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J. 2006;12(5 Suppl 2):S196–200. doi:10.1111/j.1075-122X.2006.00334.x
   PubMed Web of Science ®Google Scholar
• Morishita A, Nomura K, Tani J, et al. Galectin‑9 suppresses the tumor growth of colon cancer in vitro and in vivo. Oncol Rep. 2021;45(6):105. doi:10.3892/or.2021.8056
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun J, Ma C, et al. Reduced expression of galectin-9 contributes to a poor outcome in colon cancer by inhibiting NK cell chemotaxis partially through the Rho/ROCK1 signaling pathway. PLoS One. 2016;11(3):e0152599. doi:10.1371/journal.pone.0152599
   PubMed Web of Science ®Google Scholar
• Beyer S, Wehrmann M, Meister S, et al. Galectin-8 and −9 as prognostic factors for cervical cancer. Arch Gynecol Obstet. 2022;306(4):1211–1220. doi:10.1007/s00404-022-06449-9
   PubMed Web of Science ®Google Scholar
• Chen Z, Dong D, Zhu Y, et al. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. FASEB J. 2021;35(3):e21401. doi:10.1096/fj.202000528RR
   PubMed Web of Science ®Google Scholar
• Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5(1):29–41. doi:10.1038/nrc1527
   PubMed Web of Science ®Google Scholar
• Li CH, Chang YC, Chan MH, et al. Galectins in cancer and the microenvironment: functional roles, therapeutic developments, and perspectives. Biomedicines. 2021;9(9):1159. doi:10.3390/biomedicines9091159
   PubMed Web of Science ®Google Scholar
• Conde-Rodríguez I, Delgado-López G, Armenta-Castro E, et al. Evaluation of serum levels and expression of galectin-4 in cervical cancer. BioMed Res Int. 2020;2020:1–9. doi:10.1155/2020/6756723
   Web of Science ®Google Scholar
• Higareda-Almaraz JC, Ruiz-Moreno JS, Klimentova J, et al. Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment. BMC Cancer. 2016;16(1):680. doi:10.1186/s12885-016-2700-8
   PubMedGoogle Scholar
• Zhang L, Tian S, Pei M, et al. Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim‑3 and galectin‑9, in cervical cancer. Oncol Rep. 2019;42(6):2655–2669. doi:10.3892/or.2019.7388
   PubMed Web of Science ®Google Scholar
• Vega-Carrascal I, Bergin DA, McElvaney OJ, et al. Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung. J Immunol. 2014;192(5):2418–2431. doi:10.4049/jimmunol.1300711
   PubMed Web of Science ®Google Scholar
• Ustyanovska Avtenyuk N, Choukrani G, Ammatuna E, et al. Galectin-9 triggers neutrophil-mediated anticancer immunity. Biomedicines. 2021;10(1):66. doi:10.3390/biomedicines10010066
   PubMed Web of Science ®Google Scholar
• Nagahara K, Arikawa T, Oomizu S, et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol. 2008;181(11):7660–7669. doi:10.4049/jimmunol.181.11.7660
   PubMed Web of Science ®Google Scholar
• Zhu X, Ding M, Yu ML, et al. Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer. 2010;10(1):290. doi:10.1186/1471-2407-10-290
   PubMedGoogle Scholar
• Brown ER, Doig T, Anderson N, et al. Association of galectin-3 expression with melanoma progression and prognosis. Eur J Cancer. 2012;48(6):865–874. doi:10.1016/j.ejca.2011.09.003
   PubMed Web of Science ®Google Scholar